Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04457687 |
Expanded Access Status :
Available
First Posted : July 7, 2020
Last Update Posted : June 6, 2022
|
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Epilepsies, Myoclonic Drug Resistant Epilepsy | Drug: Lorcaserin |
Study Type : | Expanded Access |
Expanded Access Type : | Intermediate-size Population |
See clinical trials of the intervention/treatment in this expanded access record. | |
Official Title: | Extended Access Program and Retrospective Chart Review for Lorcaserin in Dravet Syndrome and Other Refractory Epilepsies |

- Drug: Lorcaserin
Lorcaserin 10 milligram (mg) tablets orally.Other Name: E2023

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 2 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Inclusion Criteria:
- Confirmed diagnosis of Dravet syndrome (according to Recommendation from a North American Consensus Panel, 2017) or other refractory epilepsy (per the judgment of the treating physician)
- Male or female, age at least 2 years at the time of informed consent
- Currently treated with lorcaserin, that the treatment is for Dravet syndrome or other refractory epilepsies, and the treatment was initiated before 13 Feb 2020; or has completed Study E2023-A001-304
- Has a clinical benefit from lorcaserin in the opinion of the treating physician
Exclusion Criteria:
None

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04457687
Contact: Eisai Medical Information | +1-888-274-2378 | esi_medinfo@eisai.com |
Responsible Party: | Eisai Inc. |
ClinicalTrials.gov Identifier: | NCT04457687 |
Other Study ID Numbers: |
E2023-A001-405 |
First Posted: | July 7, 2020 Key Record Dates |
Last Update Posted: | June 6, 2022 |
Last Verified: | May 2022 |
Extended Access Program Expanded Access Program Dravet Syndrome Refractory Epilepsies Lorcaserin |
Epilepsy Drug Resistant Epilepsy Epilepsies, Myoclonic Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Epilepsy, Generalized Epileptic Syndromes |